Annovis Bio Inc Ordinary Shares ANVS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.86
- Day Range
- $1.76–1.84
- 52-Week Range
- $1.55–5.50
- Bid/Ask
- $1.75 / $1.76
- Shares Outstanding
- 42.54M
- Market Cap
- $75.09M
- Volume/Avg
- 334,986 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 7
- Website
- https://www.annovisbio.com
Valuation
|
Metric
|
ANVS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 18.17 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ANVS
|
|---|---|
Quick Ratio | 1.11 |
Current Ratio | 1.27 |
Interest Coverage | — |
Quick Ratio
ANVS
Profitability
|
Metric
|
ANVS
|
|---|---|
Return on Assets (Normalized) | −191.30% |
Return on Equity (Normalized) | −260.17% |
Return on Invested Capital (Normalized) | −264.47% |
Return on Assets
ANVS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|hz!w!l@ | LOCK|^%nV | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|g!l@$B | LOCK|R$^! | $70B | |||
| argenx SE ADR
ARGX
| LOCK|!qm>LCc | LOCK|%& | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$tWVzY< | LOCK|&^MP^ | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|!jy@#%! | LOCK|tc | $36B | |||
| Moderna Inc
MRNA
| LOCK|k?c!N@$ | LOCK|%mL | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|%v@J?^#< | LOCK|$TS? | $25B | |||
| Incyte Corp
INCY
| LOCK|$$w>qk | LOCK|H!W | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|B$$Jlg | LOCK|%$ | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|<$tV@M | LOCK|$V | $17B |
United States